The “don’t eat me” interaction between CD47 on tumor cells and SIRPα on macrophages (and dendritic cells) allows cancer cells to evade phagocytosis. Drug development has focused on targeting CD47 via various immunotherapeutic mechanisms with the goal of allowing “eat me” signaling, and thus cancer cell recognition and clearance, to occur.